Vertex Pharmaceuticals' (VRTX) triple combination medicine deutivacaftor, tezacaftor,vanzacaftor was approved by the UK's Medicines and Healthcare products Regulatory Agency for treating cystic fibrosis in patients aged six and older with responsive CFTR mutations, including F508del, the agency said in a statement on Friday.
The treatment is marketed under the brand name of Alyftrek.
Two randomized phase 3 studies involving 480 participants aged 12 years and older, Alyftrek was found to be as effective at improving lung function as ivacaftor/tezacaftor/elexacaftor or Kaftrio, and more effective at reducing sweat chloride levels compared to placebo.
The agency said grapefruit-containing food or drink should be avoided during treatment.
The drug's common side effects include headache and diarrhoea.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。